Insider

HCA Healthcare, Inc.

HCA Health Care · 2 analyses

HCA Healthcare reported $19.8B in revenue (+3.6% YoY), compared with a +7.2% median across covered Health Care peers. 3 insider sales recorded.

Mentioned in recent filings: Tariffs

What changed

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC

LatestEarlierChange
Revenue quarter$19.8B$19.2B+3.6%
Net income quarter$1.6B$1.6B-3.9%
Diluted EPS quarter$7.27$6.96+4.5%
Dividends per share quarter$0.78$0.72+8.3%
Operating cash flow year to date$8.8B$10.3B-14.3%
Cash and cash equivalents balance$908M$1B-12.7%
Long-term debt balance$42.4B$41.6B+1.9%

Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
HCA Healthcare, Inc. HCA$19.8B+3.6%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 6, 2026Schedule 13D amendmentSCHEDULE 13D/A

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 10, 2026Erica RossittoSale3,500$505.81$1,770,335SEC
November 6, 2026Jon M FosterSale31,713$500.98$15,887,482SEC
November 4, 2026Michael J SchlosserSale1,200$494.65$593,583SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock12,429,816$5,304,299,583-4.4%Q3 2026
State Street6,991,079$2,983,373,052-6.4%Q3 2026
Wellington Management4,302,740$1,836,151,270-8.6%Q3 2026
Geode Capital Management3,506,378$1,489,380,591-4.4%Q3 2026
Norges Bank (Norway's sovereign fund)2,145,367$836,457,140—Q2 2026
Fidelity (FMR)1,472,261$628,272,750-9.8%Q3 2026
Bridgewater Associates202,141$86,261,650-0.5%Q3 2026
Millennium Management165,181$70,489,340+158.4%Q3 2026
D. E. Shaw & Co.152,696$65,161,492+9.5%Q3 2026
Citadel Advisors102,951$43,933,309-44.2%Q3 2026
Renaissance Technologies18,600$7,251,954—Q2 2026
Two Sigma Investments12,187$5,200,680+897.3%Q3 2026
T. Rowe Price237,968$101,552-7.0%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.